BioCryst Pharmaceuticals
BCRX
236 hedge funds and large institutions have $1.23B invested in BioCryst Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 99 increasing their positions, 57 reducing their positions, and 30 closing their positions.
280% more call options, than puts
Call options by funds: $18.3M | Put options by funds: $4.82M
74% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 57
1.78% more ownership
Funds ownership: 90.36% → 92.14% (+1.8%)
2% less funds holding
Funds holding: 241 → 236 (-5)
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
14% less capital invested
Capital invested by funds: $1.42B → $1.23B (-$196M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$31.7M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$15M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14.8M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$13.1M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$23.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$18.1M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$18M |
| 4 |
EP
Eversept Partners
New York
|
-$17.2M |
| 5 |
DM
Deerfield Management
New York
|
-$11.6M |
BCRX Hedge Fund Activity: Q2 2023 in Review
236 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2023, worth a combined $1.23B — down 14% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of BCRX and 26 opened new positions — a net loss of 4 holders — while 57 trimmed existing stakes and 99 added.
The largest buyer was Point72 Asset Management, adding an estimated $31.7M. The largest seller was Artisan Partners, exiting entirely with an estimated $23.7M sold.
- 236 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2023, down from 241 in Q1 2023.
- Funds reported $1.23B of BioCryst Pharmaceuticals stock for Q2 2023, down 14% quarter-over-quarter.
- 26 funds opened new BioCryst Pharmaceuticals positions in Q2 2023 and 30 closed out, a net change of -4 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2023 was Point72 Asset Management, an estimated $31.7M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2023 was Artisan Partners, an estimated $23.7M sold.
Based on aggregated 13F filings for Q2 2023.